Cochlear Limited (ASX:COH): What FY26 Results Reveal About Implants and Margins

Aditi Sarkar

02 November 2026 06:13 PM AEDT

Cochlear Limited (ASX:COH): What FY26 Results Reveal About Implants and Margins

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 sales Revenue was AUD 2,343.4 million, slightly below FY25.
Cochlear implant units increased 5% to 56,692 in FY26.
FY26 statutory net profit fell to AUD 147.3 million.
FY27 guidance anticipates underlying net profit of AUD 330–350 million.

Cochlear Limited (ASX:COH) develops hearing implants, processors and associated hearing care services. Its shares closed at AUD 140.14 on 2 November 2026. Recent 2026 company disclosures cover financial performance, operating developments and the work ahead. The relevant Business measures vary with its products, customers and funding model.

Hearing Implant and Support Services

Cochlear Limited (ASX:COH) designs and supplies implantable hearing devices, sound processors, related services and acoustic solutions for people with hearing loss. Its business comprises cochlear implants, services such as replacement sound processors, and acoustics products. Sales span the Americas, Europe, the Middle East, Africa and Asia Pacific. The company’s commercial results reflect surgical implant volumes, product mix, reimbursement and the timing of healthcare treatment. These factors also affect how unit growth translates into reported sales and profit. Information in company filings should be read by reporting period and by accounting definition. A revenue figure can describe services delivered, whereas cash receipts reflect the timing of customer payments and other movements. These measures answer different questions about the business.

FY26 Device Activity and Strategic Initiatives

In August 2026, Cochlear Limited (ASX:COH) reported 56,692 cochlear implant units for FY26, up 5% YoY. The company launched the Nucleus Nexa System and continued Investment in product development, clinical referral pathways and digital capabilities. Implant sales revenue declined 2% on a reported basis to AUD 1,435.2 million, while services revenue grew 4% to AUD 634.9 million. Acoustics revenue was AUD 273.3 million, down 1%. These differences show that a higher number of implants does not automatically produce proportional revenue growth, particularly when product pricing, geographic mix and foreign exchange change. Comparisons with the previous corresponding reporting period are useful for identifying the direction of activity, but a single reporting period does not determine a future outcome. Management targets and guidance remain subject to operating conditions and subsequent company updates.

Margins, Statutory Profit and FY27 Guidance

Cochlear Limited (ASX:COH) reported FY26 sales revenue of AUD 2,343.4 million compared with AUD 2,355.8 million for FY25, a decline of less than 1% on a reported basis. Gross Margin decreased from 74% to 71%. Research and Development costs rose 15% to AUD 323.2 million. Statutory net profit was AUD 147.3 million versus AUD 388.9 million, reflecting significant expenses and investment-related write-downs alongside underlying operating pressures. On the company’s restated comparative basis, underlying net profit was AUD 322.4 million, down 22%. Management guided to low single-digit constant-currency sales growth and underlying net profit of AUD 330–350 million in FY27.

Demand and Execution Risks

Cochlear Limited (ASX:COH) identified delays in insurance approval and broader healthcare pressures affecting time to surgery in the United States, with country-specific issues in Europe. Device pricing, Manufacturing efficiency, currency movements and reimbursement policies can influence future margins. Investment in research may require spending before product benefits are realised. The company also reported restructuring costs as part of efforts to change its cost base. Future updates on implant units, service revenue, developed-market demand, gross margin and expenditure will show whether these actions translate into the operating performance assumed in guidance.

Key Insights

Cochlear Limited (ASX:COH) increased implant units but experienced lower reported sales and a reduced gross margin in FY26. Its statutory profit reflected major significant items. The principal monitoring points are recovery in developed-market demand, product mix, execution of cost measures and delivery against FY27 Underlying Profit guidance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.